Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer
Saridakis A, Berger ER, Harigopal M, Park T, Horowitz N, Le Blanc J, Zanieski G, Chagpar A, Greenup R, Golshan M, Lannin DR. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. Annals Of Surgical Oncology 2021, 28: 5610-5616. PMID: 34426884, DOI: 10.1245/s10434-021-10518-9.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalCancer-specific survivalHigh-grade tumorsMolecular subtypesApocrine carcinomaBreast cancerBetter survivalHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Triple-negative breast cancerRare breast cancerEnd Results (SEER) databaseGrowth factor receptor 2Triple-negative patientsTriple-negative cancersLow-grade tumorsFactor receptor 2Life table methodApocrine tumorsLuminal patientsWorse survivalClinicopathologic featuresResults databaseAggressive featuresReceptor 2How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk